Table 2.
Contrasts of the AFT model lognormal for overall survival.
| Factor | Contrast | TR CI 95% |
|---|---|---|
| NLR | Continuous | 0.88 (0.81–0.95) |
| CEA, ng/ml | 240 vs 15.7 | 0.67 (0.53–0.85) |
| Time to trifluridine/tipiracil | 44.0 vs 18.5 | 1.11 (0.90–1.36) |
| Alkaline phosphatase, IU/L | 302 vs 113 | 0.86 (0.69–1.06) |
| ECOG PS | 1 vs 0 | 1.23 (0.86–1.76) |
| 2 vs 1 | 0.52 (0.38–0.72) | |
| 3 vs 1 | 0.24 (0.08–0.73) | |
| KRAS/NRAS/BRAF mutation | Yes vs No | 0.84 (0.62–1.08) |
AFT, accelerated failure time; NLR, Neutrophil–lymphocyte ratio; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; sd, standard deviation; TR, time ratio; CI, confidence interval.